BioCentury
ARTICLE | Clinical News

CDX-1127: Phase I data

November 11, 2013 8:00 AM UTC

An open-label, dose-escalation, U.S. Phase I trial in patients with relapsed or refractory lymphoid malignancies or solid tumors showed that CDX-1127 was well tolerated and led to 1 complete response ...